Found 12 matching trials
A Phase II Clinical Trial to Evaluate HLX208 in Advanced Melanoma Patients With BRAF V600 Mutation PHASE2 An open-label, multicenter phase II clinical study to evaluate safety, effi...
Show More Location
Peking University Cancer Hospita
Learn More & Join Trial
The Efficacy of HLX208 (BRAF V600E Inhibitor) for Refractory Primary Brain Tumors With BRAF Mutation After First-line Treatment PHASE2 An open-label, multicenter phase II clinical study to evaluate safety, effi...
Show More Location
Cancer Hospital Affiliated to Shandong first medical University
Learn More & Join Trial
Study on Food Influence and Drug-drug Interaction of HLX208 Tablets in Chinese Healthy Subjects PHASE1 This study is divided into Part I and Part II. Part I is the food effect st...
Show More Location
The First Affiliated Hospital of Soochow University
Learn More & Join Trial
The Efficacy and Safety of HLX208 in Adult Langerhans Cell Histiocytosis (LCH) and Erdheim-Chester Disease (ECD) With BRAF V600E Mutation PHASE2 The purpose of this study was to assess safety, efficacy and PK in adult La...
Show More Location
Peking Union Medical College Hospital
Learn More & Join Trial
The Efficacy and Safety of HLX208 in Metastatic Colorectal Cancer (mCRC) With BRAF V600E Mutation PHASE2 The purpose of this study was to assess efficacy, safety and PK in metastat...
Show More Location
Liaoning Cancer Hospital
Learn More & Join Trial
HLX208 (BRAF V600E Inhibitor) in Combination With Trametinib in Patients With Advanced Solid Tumors PHASE1 A phase I clinical trial evaluating the safety, tolerability, pharmacokinet...
Show More Location
Sun Yat-sen University Cancer Center
Learn More & Join Trial
The Efficacy and Safety of HLX208 in Advanced Anaplastic Thyroid Cancer (ATC) With BRAF V600 Mutation PHASE1 The purpose of this study was to assess efficacy, safety and PK in anaplast...
Show More Location
Fudan University Affiliated Oncology Hospital
Learn More & Join Trial
A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of HLX208+HLX10 in NSCLC With BRAF V600E Mutation PHASE1 An open-label, multicenter phase Ib/II clinical study to evaluate safety, t...
Show More Location
Shanghai Chest Hospital, Shanghai Jiao Tong University, School of Medicine
Learn More & Join Trial
A Phase II Clinical Trial to Evaluate HLX208 in Advanced Non-small Cell Lung Cancer Patients With BRAF V600 Mutation PHASE2 Evaluate the efficacy,safety and pharmacokinetics of HLX208 in advanced non...
Show More Location
Shanghai chest hospital
Learn More & Join Trial
The Efficacy of HLX208 (BRAF V600E Inhibitor) With Cetuximab for Metastatic Colorectal Cancer (mCRC) With BRAF V600E Mutation After First-line Treatment PHASE2 An open, multicenter phase II clinical study to evaluate safety and efficac...
Show More Location
Fudan University Affiliated Oncology Hospital
Learn More & Join Trial